Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company

Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by

Novartis verzeichnet ein starkes zweites Quartal mit zweistelligem Umsatzwachstum und erhöhter Kerngewinnmarge; Prognose für das operative Kernergebnis im Geschäftsjahr 2025 angehoben

Novartis verzeichnet ein starkes zweites Quartal mit zweistelligem Umsatzwachstum und erhöhter Kerngewinnmarge; Prognose für das operative Kernergebnis im Geschäftsjahr 2025 angehoben
arcticnovartis

Ad-hoc-Mitteilung gemäss Art. 53 KR 

/by

Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance

Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by

Novartis receives approval for first malaria medicine for newborn babies and young infants

Novartis receives approval for first malaria medicine for newborn babies and young infants
arcticnovartis

  • Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants
  • Rapid approvals in eight African countries now expected under a special global health scheme run by Swiss agency for therapeutic products (Swissmedic)
  • Novartis plans to introduce infant-friendly Coartem Baby on largely not-for-profit basis to increase access in areas where malaria is endemic

Basel, July 8, 2025 – Novartis today announced Coartem

/by

Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)

Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
arcticnovartis

  • The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1
  • Safety in GCA patients was consistent with known safety profile of Cosentyx® (secukinumab)1

Basel, July 03, 2025 – Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).

/by